May 31, 2026 — RNews

#nsclc — Sunday, May 31, 2026 (1 items)

hot top new

← prev day next day →

0

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China. (linkinghub.elsevier.com)

Lu S … Xia MY The Lancet 2026-05-31

#cancer #clinical trial #immunotherapy #chemotherapy #nsclc